Agios Pharmaceuticals, Inc. (AGIO) vs Trevi Therapeutics, Inc. (TRVI)

Agios Pharmaceuticals, Inc. and Trevi Therapeutics, Inc. are both Biotechnology companies. Agios Pharmaceuticals, Inc. and Trevi Therapeutics, Inc. are of similar size ($1.9B and $1.9B). Trevi Therapeutics, Inc. has the higher net margin (0.00% vs −264.8%) and the lower return on invested capital (−1,309.1% vs −75.0%). Across the 13 metrics below, Trevi Therapeutics, Inc. leads on 9 and Agios Pharmaceuticals, Inc. on 4.

Valuation

Metric AGIO TRVI Biotechnology median
P/E n/m n/m 11.36
P/S 13.43 n/m 9.12
P/B 1.93 7.23 2.14
Price to free cash flow n/m n/m 26.34
EV/EBITDA n/m n/m 0.62
EV/Sales 8.95 n/m 8.56
Earnings yield (19.95%) (2.88%) (34.18%)
Free cash flow yield (17.77%) (2.82%) (23.62%)

Profitability

Metric AGIO TRVI Biotechnology median
Gross margin 93.81% 0.00% 67.24%
Operating margin (297.72%) 0.00% 0.00%
Net margin (264.76%) 0.00% 0.00%
Free cash flow margin (238.54%) 0.00% 0.00%
Return on equity (32.95%) (24.67%) (50.28%)
Return on assets (30.44%) (23.82%) (45.89%)
Return on invested capital (75.02%) (1,309.12%) 0.00%

Growth

Metric AGIO TRVI Biotechnology median
Revenue growth (TTM) 214.44% — 6.96%
EPS growth (last fiscal year) (161.17%) 31.91% 29.86%
Revenue growth, 5-year CAGR (14.45%) — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AGIO TRVI Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 9.69 38.86 4.72
Net debt to EBITDA 1.80 3.83 1.01

Dividend

Metric AGIO TRVI Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric AGIO TRVI Biotechnology median
Market cap 1.90b 1.94b 167.45m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack